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Abstract 
Background: Acute myocardial infarction (AMI) is a severely life-threatening 
cardiovascular disease. Previous research has identified an association between the 
P2X7 receptor (P2X7R) and the development of atherosclerosis. However, the 
correlation of its expression with the clinical prognosis of patients with AMI remains 
unclear. The present study aimed to investigate the potential role of P2X7R in Chinese 
patients with AMI.  
Methods: Seventy-nine patients with AMI and 48 controls were consecutively 
enrolled in this prospective observational study. Circulating P2X7R mRNA 
expression levels and other clinical variables were determined upon admission to the 
hospital. Patients were followed up for 360 days, and the end-point was considered as 
the occurrence of major adverse cardiovascular events (MACE).  
Results: Circulating P2X7R mRNA expression level in peripheral blood mononuclear 
cells of patients with AMI were significantly higher than those in controls and had 
promising diagnostic ability of AMI with an area under the curve of 0.928. 
Furthermore, P2X7R was demonstrated to be correlated positively with the severity of 
coronary artery stenosis. Additionally, this is the first study to indicate that higher 
P2X7R mRNA expression is associated with a higher rate of MACE within 360 days 
after AMI.  
Conclusions: The present study showed that the circulating level of P2X7R was 
elevated in AMI patients and was closely associated with the severity of coronary 
artery stenosis and prognosis of AMI. 
Keywords: P2X7R, acute myocardial infarction, coronary artery stenosis, 
prognosis 
 
 
Introduction 
Myocardial infarction, a cardiovascular disease that severely threatens human 
health, is primarily caused by atherosclerosis of the coronary artery. Pathogenesis of 
atherosclerosis involves the accumulation of lipids and leukocytes in the intima of 
blood vessel walls leading to plaque, inflammation, and alteration of innate and 
adaptive immunities [1, 2]. Rupture of the vulnerable plaque, characterized by a thin 
fibrous cap and lipid-rich core is the main cause of coronary thrombosis at the site of 
plaque, leading to acute myocardial infarction (AMI) [3].  
Purinergic receptor P2X7 (P2X7R) is a ligand-gated cation channel that is 
significantly expressed in original immune cells. P2X7R is the most compelling 
member of the purinergic receptor family owing to its unique phenotype and is 
involved in the production and activation of inflammatory cytokine interleukin-1 beta 
for the modulation of inflammatory responses [4]. Research has demonstrated that 
P2X7R is highly expressed in endothelial cells and macrophages infiltrating the 
atherosclerotic plaques in human carotid arteries [5]. Peng et al. [6] reported that 
P2X7R plays a crucial role in the development of atherosclerosis through the 
regulation of NLRP3 inflammasome activation. Interestingly, rheumatoid arthritis is 
coupled with increased incidence of myocardial infarction, and the severity of arthritis 
has been proven to be reduced in P2X7 receptor knockout mice [7]. 
This accumulating evidence suggests the possibility of an association between 
P2X7R and the development of atherosclerosis; however, the significance of its 
expression in clinical patients with AMI remains unclear. The present study was 
conducted to investigate the potential role of P2X7R in AMI. 
 
Methods 
Study subjects 
Seventy-nine patients with AMI (ICD-9 codes 410), undergoing coronary 
angiography in the cardiac care unit of the First Affiliated Hospital of Wenzhou 
Medical College (China), were consecutively recruited for the present study (Table 1). 
AMI, including ST-segment elevation myocardial infarction (STEMI) and non-ST-
segment elevation myocardial infarction (NSTEMI), was diagnosed based on the 
presence of two of the following criteria: prolonged chest pain; typical 
electrocardiogram ECG changes; and increased troponin I level (> 0.15 μg/L). The 
control group comprised 48 patients recruited from the cardiology department. These 
patients presented chest discomfort and certain risk factors for coronary disease, but 
their coronary angiography results were normal. Exclusion criteria included patients 
with ischemic stroke history, peripheral vascular disease, hematological diseases, 
acute or chronic inflammation, liver dysfunction (2 times higher than the upper limit 
of the reference range of AST/ALT), severe renal dysfunction (chronic kidney disease 
stage: G4–5), autoimmune disease, and cancer. 
Patients in both AMI and control groups were treated with dual antiplatelet 
therapy and statin as per standard protocol after hospitalization. Gensini scores were 
used to evaluate the severity of coronary stenotic lesions and was calculated by two 
technicians based on imaging results taken at different angles of the 
angiocardiography. 
Written informed consent was obtained from all subjects before enrollment into 
this study. The study was approved by the Medical Ethics Committee of the First 
Affiliated Hospital of Wenzhou Medical College (No. 2017-145) and was performed 
in accordance with the Declaration of Helsinki. 
All patients underwent clinical follow-up for one complete year after discharge, 
to determine the end point based on the findings at the last visit or last telephone call. 
However, some patients were lost during follow-up for various reasons. The 
composite end point was major adverse cardiovascular events (MACE), which 
included all-cause death, myocardial infarction, target lesion revascularization, heart 
failure, and recurrent angina, which were identified through phone-calls or 
hospitalization. 
 
Sample collection 
In the AMI group, emergency coronary angiography or percutaneous coronary 
intervention was performed within 12 h of symptom onset, and blood samples were 
collected immediately after the procedure. In the control group, blood samples were 
obtained immediately after coronary angiography following their admission. 
Peripheral venous blood was drawn from the antecubital vein while the patients were 
in a fasting state. Blood was collected with EDTA as an anticoagulant. Peripheral 
blood mononuclear cells (PBMCs) were immediately isolated from peripheral venous 
blood using Ficoll density gradient centrifugation. 
 
Quantitative real-time PCR 
RNA extraction from PBMCs was performed according to manufacturer protocol 
(using TRIzol, Invitrogen). Synthesis of cDNAs was performed by reverse 
transcription with 2 μg of total RNA using a cDNA Transcription kit (Thermo Fisher 
Scientific), as described by the manufacturer. Real-time polymerase chain reactions 
(PCR) were performed by SYBR Premix Ex Taq Kit (TaKaRa, Japan) according to 
manufacturer instructions. The PCR reactions were evaluated by the ABI-7500 
Sequence Detection System. The primer sequences used in the study were as follows: 
P2X7R (NM_002562.5), forward: 5′-GAACAATATCGACTTCCCCGG -3′, reverse: 
5′-TTATCGCCTGTTTCTCGGAAG -3′; GAPDH (NM_001256799.2), forward: 5′-
CAGGAGGCATTGCTGATGAT -3′, reverse: 5′-GAAGGCTGGGGCTCATTT-3′. 
Values were normalized to that of the housekeeping gene GAPDH. According to 
manufacturer guidelines, the ΔΔCt method was used to determine relative expression 
levels. Statistical analyses were performed using ΔΔCt values. 
 
Statistical analysis 
Statistical analysis was performed using SPSS v.20 software (SPSS Inc., Chicago, 
IL). All clinical data were represented as mean ± standard deviation for continuous 
variables, and as number (%) for incidence rates. Independent-samples T test or the 
Wilcoxon Rank Sum Test was used for comparison of the two groups of individuals. 
Chi-square test was used to compare proportions. The association between relative 
levels of P2X7R and follow-up endpoints was ascertained by the Kaplan-Meier 
analysis. Receiver operating characteristic (ROC) curve analysis was performed to 
assess P2X7R as a predictor for distinguishing AMI from non-AMI. Correlations 
between variables were determined with the Spearman test. The univariate and 
multivariate cox regression analysis was performed to assess P2X7R expression levels 
and risk of MACE after myocardial infarction. In all tests, a value of p < 0.05 was 
considered statistically significant. 
 
Results 
Baseline characteristics of patients 
The baseline characteristics of patients are shown in Table 1. There were 73 cases 
of STEMI and 6 cases of NSTEMI in the AMI group. Among them, 76 cases were 
treated with emergency PCI and 3 cases were treated with elective CABG after 
coronary angiography. No statistical difference in age, hypertension, diabetes, 
triglycerides, high-density lipoprotein (HDL), thyroxine, and uric acid was observed 
between the two groups. The AMI group had higher values of male-to-female ratio, 
proportion of smoking, total cholesterol (TC), low-density lipoprotein (LDL), white 
blood count (WBC), red cell distribution width (RDW), and C-reactive protein (CRP) 
(p < 0.01) than the control group. 
 
P2X7R mRNA expression levels 
The P2X7R mRNA expression in PBMCs of 127 blood samples, determined by 
quantitative real-time PCR, is shown in Figure 1. The AMI group had 2.85-fold higher 
P2X7R mRNA expression than the control group (2.81 ± 0.15 vs. 0.99 ± 0.06, p < 
0.01, Fig. 1). 
 
P2X7R mRNA levels and stenosis 
As shown in Figure 2A, significantly higher P2X7R mRNA expression was 
detected in patients with AMI with three-vessel lesions than in patients with single-
vessel lesions (p < 0.05). A significant Spearman correlation coefficient was noted 
between angiographic Gensini scores and circulating P2X7R mRNA expression levels 
(r = 0.36, p < 0.01, Fig. 2B). Additionally, P2X7R mRNA expression levels were 
found to be positively correlated with serum LDL and CRP values (r = 0.31 and 0.46, 
p < 0.05; Fig. 2C, D). 
 
The diagnostic ability of P2X7R in AMI 
ROC analysis was performed to determine the diagnostic ability of P2X7R in 
AMI. The ROC curves of P2X7R mRNA expression levels in PBMCs could 
distinguish between the AMI and control groups with an area under the curve (AUC) 
of 0.928 (95% confidence interval [CI] 0.885–0.971, p < 0.01, Fig. 3). The ROC 
curves revealed that the cut-off value of P2X7R mRNA expression in PBMCs 
differentiating patients with AMI from control subjects was 1.418.  
 
P2X7R mRNA and MACE 
Patients enrolled in this study were followed up for 360 days. Fourteen patients 
were lost to follow-up. All subjects were divided into two groups according to fold 
changes of P2X7R mRNA by dichotomization: the lower level (0.52–2.68-fold 
changes) and the higher level (2.69–5.42-fold changes). The end point incidence 
significantly differed according to P2X7R expression levels, as analyzed using the 
Kaplan–Meier curve (χ2 = 5.29, p = 0.021; Fig. 4). The univariate and multivariate 
cox regression analysis revealed that P2X7R expression levels significantly increased 
the risk of MACE after myocardial infarction (hazard ratio [HR] 2.87, 95% CI 1.11–
7.42 and HR 3.28, 95% CI 1.12–9.65; Table 2). 
 
Discussion 
Atherosclerosis is thought to be the primary cause of AMI. Initiation, progression, 
and complications of atherosclerotic plaque are considered to be a result of the 
complex phenomena involving the interplay of lipoproteins, vascular wall 
components, blood cells, and the immune system. Multiple levels of evidence support 
a close relationship between inflammation and atherosclerosis. 
P2X7R is considered to play dual roles in several inflammatory pathological 
conditions [8]. P2X7R functions as a second signal during NLRP3 inflammasome 
activation and interleukin (IL)-1β release. It contributes to activation of effector T 
cells, favors polarization of T cells into Th17 cells, and reduces suppressive activity 
and viability of Tregs. On the other hand, P2X7R can induce an excessive production 
and release of inflammatory mediators coupled to a high incidence of apoptotic and 
necrotic cell death due the release of large amounts of ATP, which causes a self-
sustained pro-inflammatory deleterious cycle.  
In the present study, it was found that P2X7R mRNA expression levels were 
elevated in PBMCs of patients with AMI, and evaluated the diagnostic ability of 
P2X7R using ROC analyses. The AUC for P2X7R was 0.928 (95% CI 0.885–0.971) 
for differentiating between patients with AMI from control subjects. Furthermore, the 
indicated P2X7R was positively correlated with severity of coronary artery stenosis, 
and was linearly correlated with serum LDL and CRP. Based on a current 
understanding, P2X7R clearly plays a key role in cardiovascular physiology and 
pathophysiology. It shows deleterious effects in cardiovascular diseases by promoting 
inflammation, thrombosis, and endothelial dysfunction [9]. Its activation promotes the 
assembly of NLRP3 inflammasome and an unconventional release of pro-
inflammatory leaderless cytokines IL-1 beta and IL-18 [10]. A previous study 
illustrated that inhibition of P2X7R may be able to suppress the AMPK/MAPK 
signaling pathway and consequently downregulate both EMMPRIN and MMP-9 
expression in monocyte-derived macrophages, which correlated with advanced 
atherosclerotic lesions, followed by plaque rupture and myocardial infarction [11]. 
Furthermore, Stachon et al. [12] found that P2X7 receptor is highly expressed in 
murine atherosclerotic lesions, particularly in lesioned macrophages, and P2X7-
deficient mice showed smaller atherosclerotic lesions than P2X7-competent mice after 
16 weeks of a high cholesterol diet. All of these effects together suggest that P2X7R, 
indeed participates in the development of atherosclerosis. 
However, data on the relationship between P2X7R and MACE after AMI remains 
insufficient. The inhibition of P2X7 receptor attenuated sympathetic nerve sprouting 
after myocardial infarction via the NLRP3/IL-1β pathway, which contributes to neural 
and cardiac remodeling [13]. Microglial P2X7R in rat hypothalamic paraventricular 
nuclei regulate the sympathoexcitatory responses in AMI [14]. NONRATT021972 
siRNA decreases the upregulation of P2X7R and improves cardiac function after 
myocardial ischemia [15].According to available research, this is the first report to 
propose that a higher expression of P2X7R mRNA is independently associated with 
higher rate of MACE within 360 days of AMI. Although inflammatory markers, such 
as hs-CRP, have been shown to identify patients with increased risk for incident 
coronary heart disease [16], but there were no significant associations between hs-
CRP levels after AMI and their symptoms, function and quality of life after adjusting 
for prior health status [17]. Giuliani et al. [18] found correlation of P2X7R and CRP 
was widely different depending on the disease and best correlation was found in 
patients suffering of ischemia. So P2X7R measurement might complement that of 
CRP in a differential diagnosis of inflammatory conditions of different etiology. 
 
Limitations of the study 
Nevertheless, this study did have several limitations. Firstly, it was a single-center 
study with a relatively small study population; changes in long-term clinical outcomes 
may need to be confirmed by increasing both the total number of patients and the 
duration of follow-up. Secondly, this study lacked cardiac remodeling data during the 
follow-up period; therefore, further studies are warranted. Thirdly, measurement of 
P2X7 protein was lacking which should be required in further study. 
 
Conclusions 
The present study identified that the purinergic receptor P2X7R was elevated in 
AMI patients and was closely associated with the severity of coronary artery stenosis 
and prognosis of AMI. 
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Table 1. Characteristics of patients with acute myocardial infarction (AMI) and 
controls 
 AMI (n = 79) Controls (n = 48)  p 
Age [years] 62.9 ± 12.9 64.8 ± 10.3 0.393 
Male 65 (79.5%) 26 (54.2%) 0.001* 
Hypertension 44 (55.6%) 33 (68.8%) 0.144 
Diabetes 19 (24.1%) 11 (22.9%) 0.884 
Smoking 42 (53.2%) 13 (27.1%) 0.004* 
Laboratory parameters: 
TC [mmol/L] 4.91 ± 1.1 4.27 ± 0.9 0.001* 
TG [mmol/L] 1.40 ± 1.3 1.57 ± 0.7 0.435 
LDL [mmol/L] 3.09 ± 0.9 2.58 ± 0.9 0.004* 
HDL [mmol/L] 1.07 ± 0.2 1.12 ± 0.3 0.385 
WBC [×109/L] 8.97 ± 3.0 6.56 ± 1.8 0.000* 
Thyroxine [nmol/L] 97.49 ± 27.1 104.16 ± 23.4 0.163 
RDW [%] 13.47 ± 1.0 13.03 ± 0.8 0.008* 
CRP [mg/L] 23.61 ± 19.5 5.15 ± 7.3 0.000* 
sUA [μmol/L] 366.5 ± 103.6 362.3 ± 91.4 0.820 
Data presented as mean ± standard deviation for variables; TC — total cholesterol; TG 
— triglycerides; LDL — low–density lipoprotein; HDL — high–density lipoprotein; 
WBC — white blood count; RDW — red–cell distribution width; CRP — C–reactive 
protein; sUA — serum uric acid; *p < 0.05 AMI vs. control 
 
 
 
Table 2. The correlations of the P2X7R mRNA expression level with major adverse 
cardiovascular events after acute myocardial infarction using the uni‐  and 
multivariate Cox analysis. 
Factors 
 
Univariate Cox Multivariate Cox 
 
HR (95% CI)        P HR (95% CI)       P 
 
Age  1.01 (0.98–1.04) 0.640 1.00 (0.96–1.05) 0.860 
Sex  0.43 (0.25–1.83) 0.669 0.46 (0.11–1.96) 0.294 
Hypertension  5.09(1.50–17.32) 0.009 3.60 (1.02–12.74) 0.047 
Diabetes  2.39 (1.01–5.69) 0.049 1.26 (0.46–3.41) 0.652 
Smoking  1.30 (0.55–3.10) 0.547 1.68 (0.53–5.29) 0.380 
Total cholesterol  0.91 (0.61–1.35) 0.632 1.04 (0.36–3.01) 0.942 
LDL-C  0.83 (0.50–1.37) 0.465 0.74 (0.20–2.75) 0.652 
Higher P2X7R 
level 
2.87 (1.11–7.42) 0.029* 3.28 (1.12–9.65) 0.031* 
*Patients with a lower level of P2X7R mRNA expression (0.52–2.68-fold changes) 
were set as the reference group. CI — confidence interval; HR — hazard ratio; LDL-C 
— low-density lipoprotein; higher P2X7R level, 2.69–5.42-fold changes of P2X7R 
mRNA expression level 
 
 
 
 
Figure 1. Circulating P2X7R mRNA expression levels in the acute myocardial 
infarction and control groups. Data are presented as the mean ± standard error of the 
mean; *p < 0.01 compared to the control. 
 
Figure 2. Pattern of circulating P2X7R expression levels in patients with acute 
myocardial infarction (AMI); A. Relative P2X7R levels in patients with 1, 2, or 3 
affected branches (n = 1, 2, and 3); red lines represent the mean values; B. 
Correlations between plasma P2X7R levels and coronary Gensini scores in patients 
with AMI (r = 0.36, p < 0.05); C. Correlations between plasma P2X7R levels and 
serum low-density lipoprotein cholesterol; D. Correlations between plasma P2X7R 
levels and serum C-reactive protein. 
 
Figure 3. Receiver operating characteristic (ROC) curve analysis of P2X7R 
expression level in PBMCs to predict acute myocardial infarction. 
 
Figure 4. Kaplan–Meier curve analysis of patients free of end point after acute 
myocardial infarction, according to P2X7R mRNA expression level. The end point 
was defined as all-cause death, myocardial infarction, target lesion revascularization, 
heart failure, and recurrent angina. 
 




